Contact: John Sterling, 914-740-2196, firstname.lastname@example.org
Impact of Immunotherapy Felt Far Beyond Immuno-oncology
New Rochelle, NY, December 2, 2016—Applications of immunotherapy extend beyond its current prevalent use for cancer, according to a special immunotherapy supplement published by Genetic Engineering & Biotechnology News (GEN).
“Immunotherapies’ promise for cancer has captured the most attention to date,” says John Sterling, Editor in Chief of GEN. “Now, its expanded potential benefits are being fully explored in such areas as sepsis, autoimmune disorders, HIV, hepatitis, and organ transplantation.”
The GEN Immunotherapy Supplement highlights CytoSorb, which is an approved extracorporeal cytokine absorber in the European Union. In one study, patients in septic shock with multi-organ failure experienced improved survival when treated with CytoSorb within the first 24 hours.
“Sepsis is known to kill 30 million people worldwide each year,” adds Sterling. “This treatment exemplifies the potential of immunotherapeutic interventions beyond oncology.”
The GEN Immunotherapy Supplement includes the following features: Immunotherapy Encompasses More than Immuno-oncology, Developing Biomarkers for Improved Therapeutics, Treating Solid Tumors with CAR T Cells, Circumventing Cancer Cells’ Defenses, and a Therapeutic Cancer Vaccine Roundup.
You can access the supplement here.
Genetic Engineering & Biotechnology News (GEN), published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. Covering bench to bedside for over 35 years, GEN includes articles on Drug Discovery, Bioprocessing, OMICS, and Translational Medicine.